Performance of ROIV Roivant Sciences | 24.2% in 12m
Compare ROIV with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Roivant Sciences with its related Sector/Index XBI
Performance Duell ROIV vs XBI
| TimeFrame | ROIV | XBI |
|---|---|---|
| 1 Day | -1.58% | -1.52% |
| 1 Week | 0.90% | 3.45% |
| 1 Month | 7.57% | 7.71% |
| 3 Months | -3.11% | -2.11% |
| 6 Months | 25.2% | 25.51% |
| 12 Months | 24.2% | 6.37% |
| YTD | -1.06% | 1.05% |
| Rel. Perf. 1m | -0.05 | |
| Rel. Perf. 3m | 0.07 | |
| Rel. Perf. 6m | -0.48 | |
| Rel. Perf. 12m | 1.55 |
Is Roivant Sciences a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Roivant Sciences (NASDAQ:ROIV) is currently (May 2024)
not a good stock to buy. It has a ValueRay Fundamental Rating of -45.29 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ROIV as of May 2024 is 10.16. This means that ROIV is currently overvalued and has a potential downside of -9.53% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ROIV as of May 2024 is 10.16. This means that ROIV is currently overvalued and has a potential downside of -9.53% (Sold with Premium).
Is ROIV a buy, sell or hold?
- Strong Buy: 7
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
Values above 0%: ROIV is performing better - Values below 0%: ROIV is underperforming
Compare ROIV with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -0.75% | 1.80% | 6.91% | -5.12% |
| US NASDAQ 100 | QQQ | -1.29% | 1.48% | 7.73% | -13.12% |
| US Dow Jones Industrial 30 | DIA | -0.46% | 1.40% | 9.73% | 2.21% |
| German DAX 40 | DBXD | 1.30% | 2.60% | 8.21% | 7.46% |
| UK FTSE 100 | ISFU | -0.60% | -2.23% | 8.34% | 8.86% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -0.21% | 3.05% | 21.87% | 31.90% |
| Hongkong Hang Seng | HSI | -2.83% | -15.71% | 20.16% | 29.59% |
| Japan Nikkei 225 | EXX7 | 0.53% | 8.07% | 13.71% | 12.42% |
| India NIFTY 50 | INDA | -2.21% | 3.65% | 7.62% | -4.49% |
| Brasil Bovespa | EWZ | 0.46% | 2.33% | 27.03% | 11.90% |
ROIV Roivant Sciences vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -0.10% | 4.26% | 6.69% | -13.25% |
| Consumer Discretionary | XLY | 0.56% | 3.87% | 17.86% | 4.56% |
| Consumer Staples | XLP | 0.14% | 0.99% | 10.96% | 18.65% |
| Energy | XLE | -0.30% | 6.69% | 11.08% | -0.99% |
| Financial | XLF | -0.68% | 0.52% | 2.78% | -8.84% |
| Health Care | XLV | -0.99% | 1.89% | 10.19% | 10.73% |
| Industrial | XLI | 1.18% | 4.09% | 5.51% | -4.10% |
| Materials | XLB | 0.56% | 4.03% | 9.18% | 3.61% |
| Real Estate | XLRE | -1.61% | -0.91% | 15.56% | 14.25% |
| Technology | XLK | -2.16% | 1.05% | 8.88% | -14.08% |
| Utilities | XLU | -0.60% | -5.32% | 7.00% | 11.55% |
| Aerospace & Defense | XAR | 0.13% | -0.89% | 9.66% | 0.08% |
| Biotech | XBI | -2.55% | -0.14% | -0.31% | 17.86% |
| Homebuilder | XHB | 1.22% | 1.23% | -5.31% | -26.62% |
| Retail | XRT | -1.18% | 0.11% | 4.36% | -0.96% |
Does Roivant Sciences outperform its market, is ROIV a Sector Leader?
Yes, over the last 12 months Roivant Sciences (ROIV) made 24.23%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.37%.
Over the last 3 months ROIV made -3.11%, while XBI made -2.11%.
Yes, over the last 12 months Roivant Sciences (ROIV) made 24.23%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.37%.
Over the last 3 months ROIV made -3.11%, while XBI made -2.11%.
| Period | ROIV | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 7.57% | 7.71% | 5.77% |
| 3 Months | -3.11% | -2.11% | 6.32% |
| 12 Months | 24.23% | 6.37% | 29.35% |